- Conditions
- Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Interventions
- Pioglitazone, Tyrosine Kinase Inhibitor (TKI)
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 16 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 257
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- LY2189265, Exenatide, Placebo, Metformin, Pioglitazone
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 978 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 78
- States / cities
- Goodyear, Arizona • Phoenix, Arizona • Cathedral City, California + 75 more
- Conditions
- Polycystic Ovary Syndrome
- Interventions
- pioglitazone, Placebo
- Drug
- Lead sponsor
- Virginia Commonwealth University
- Other
- Eligibility
- 18 Years to 40 Years · Female only
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 1
- States / cities
- Richmond, Virginia
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Tesaglitazar, pioglitazone
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 45 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 21
- States / cities
- Pasadena, California • Washington D.C., District of Columbia • Gainesville, Florida + 18 more
- Conditions
- Chronic Kidney Diseases
- Interventions
- Pioglitazone, Placebo
- Drug · Other
- Lead sponsor
- The University of Texas at Arlington
- Other
- Eligibility
- 35 Years to 70 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 2
- States / cities
- Arlington, Texas • Dallas, Texas
- Conditions
- Diabetes Mellitus
- Interventions
- TAK-379, Pioglitazone, Placebo
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 323 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 8
- States / cities
- Artesia, California • Norwalk, California • Santa Ana, California + 5 more
- Conditions
- Type II Diabetes Mellitus
- Interventions
- pioglitazone
- Other
- Lead sponsor
- Arizona State University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 2
- States / cities
- Tempe, Arizona
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Placebo, Linagliptin
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years to 79 Years
- Enrollment
- 278 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2009
- U.S. locations
- 29
- States / cities
- Escondido, California • Greenbrae, California • Los Angeles, California + 25 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- CS-917, metformin hydrochloride, pioglitazone
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 66
- States / cities
- Birmingham, Alabama • Northport, Alabama • Mesa, Arizona + 62 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- vildagliptin, thiazolidinedione (TZD)
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 2,665 participants
- Timeline
- Started 2006
- U.S. locations
- 1
- States / cities
- East Hanover, New Jersey
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Diabetes mellitus Type 2 De-escalation treatment (DET)
- Drug
- Lead sponsor
- Sciema UG
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- vildagliptin, pioglitazone
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 318 participants
- Timeline
- 2004 – 2006
- U.S. locations
- 1
- States / cities
- East Hanover, New Jersey
- Conditions
- Diabetes Mellitus, Type 2, Cardiovascular Diseases
- Interventions
- Canagliflozin, Empagliflozin, Dapagliflozin, Dipeptidyl Peptidase-4 (DPP-4) Inhibitors, Glucagon-like Peptide-1 (GLP-1) Agonist, Anti-hyperglycemic Agents (AHA), Thiazolidinediones (TZD), Sulfonylureas (SU), Insulin
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- Not listed
- Enrollment
- 714,582 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018
- U.S. locations
- 1
- States / cities
- Titusville, New Jersey
- Conditions
- Inflammation
- Interventions
- Pioglitazone 15mg, pioglitazone 30mg, placebo
- Drug
- Lead sponsor
- University at Buffalo
- Other
- Eligibility
- 20 Years to 65 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Ends 2003
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Diabetes Mellitus
- Interventions
- Alogliptin and pioglitazone, Pioglitazone
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 493 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 64
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Anaheim, California + 61 more
- Conditions
- Hepatitis
- Interventions
- Actos (Pioglitazone)
- Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2009
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Non-Alcoholic Fatty Liver Disease, Type 2 Diabetes, Mitochondrial Metabolism Disorders
- Interventions
- Pioglitazone, Placebo
- Drug · Other
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 2
- States / cities
- San Antonio, Texas
- Conditions
- Healthy
- Interventions
- Cenicriviroc, Pioglitazone
- Drug
- Lead sponsor
- Tobira Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Lakewood, Colorado
- Conditions
- Diabetes Mellitus Type 2
- Interventions
- metformin, pioglitazone, placebo, taspoglutide
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 326 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 76
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Muscle Shoals, Alabama + 68 more
- Conditions
- Lipodystrophy, HIV Infection
- Interventions
- Metformin, Pioglitazone
- Drug
- Lead sponsor
- Tufts Medical Center
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Severe, Refractory Asthma, Airway Inflammation, Airflow Obstruction
- Interventions
- Pioglitazone, Placebo
- Drug
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2016
- U.S. locations
- 2
- States / cities
- Bethesda, Maryland • Falls Church, Virginia
- Conditions
- Obese, Metabolic Syndrome
- Interventions
- Mirabegron, Pioglitazone, Mirabegron and Pioglitazone
- Drug
- Lead sponsor
- Philip Kern
- Other
- Eligibility
- 35 Years to 65 Years
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 1
- States / cities
- Lexington, Kentucky
- Conditions
- Diabetes Mellitus
- Interventions
- Oral Anti-diabetes Drugs alone, Basal bolus insulin, Supplemental insulin, Continuous glucose monitoring (CGM)
- Drug · Device
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 85 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 3
- States / cities
- Atlanta, Georgia
- Conditions
- Cardiovascular Events, Type2 Diabetes, Renal Disease
- Interventions
- SGLT2 inhibitor, DPP-4 inhibitor, GLP-1RA, 2nd generation SU
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 781,430 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts